EX-10.69



 Exhibit 10.69 

EMPLOYMENT AGREEMENT 

This Employment Agreement (this “Agreement”) is entered into as of March 17, 2014 (“Effective Date”), by and between
Cancer Genetics, Inc., a Delaware corporation (the “Company”), and Edward J. Sitar (“Employee”). 
 In consideration of
the mutual covenants and conditions set forth herein, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows: 

1. Employment. The Company hereby employs Employee in the capacity of the Chief Financial Officer and Treasurer of the Company, reporting directly to
the President and Chief Executive Officer of the Company (the “CEO”). Employee accepts such employment and agrees to perform such roles and provide such management and other services for the Company as are customary to such office and such
additional responsibilities, consistent with his position as the Company’s Chief Financial Officer and Treasurer, as may be assigned to him from time to time by the CEO. All employees in the financial operations, public company related
financial reporting, accounting, general office administration and human resources departments of the Company shall report, directly or indirectly, to Employee, and Employee shall make (or delegate to others) all employment decisions regarding and
with respect to direct and indirect reports. 
 2. Term. 

2.1 The employment hereunder shall be for a period commencing on April 1, 2014 (the “Commencement Date”) and ending on the one
year anniversary of the Commencement Date (the “Initial Term”), unless earlier terminated as provided in Section 4 or 5. This Agreement shall be automatically renewed for successive one-year periods thereafter, commencing upon the
expiration of the Initial Term, unless earlier terminated as provided in Section 4 or 5. Employee’s employment following the Commencement Date will be on a full-time business basis requiring the devotion of substantially all of his
productive business time for the efficient and successful operation of the business of the Company. 
 2.2 During the period between the
Effective Date and Commencement Date, Employee shall serve as an employee and will perform such tasks and duties related to the organization, operation and growth of the Company as the CEO and Employee reasonably and mutually agree, subject to
Employee’s availability and prior commitments. 
 2.3 Employee agrees that for the period between March 17, 2014 and April 1,
2014 that he will be paid at a weekly rate equivalent to the Base Compensation. 
 3. Compensation and Benefits 

3.1 Cash Compensation. 

(a) For the performance of Employee’s duties hereunder following the Commencement Date, the Company shall pay Employee an annual salary
in the amount of $260,000 or such greater amount as may be determined by the Board of Directors of the Company (the “Base Compensation”). The annual salary shall be paid in installments either every two weeks or twice per month, based on
and in accordance with Company’s regular payroll procedures. 

  
  

					
	1	 	EDWARD J. SITAR – CFO EMPLOYMENT AGREEMENT CGIX	 	CGIX                









 (b) Company shall compensate Employee as they reasonably and mutually agree for Employee’s
performance of work during the period between the Commencement Date and the date of this Agreement pursuant to Section 2.2. 
 3.2
Bonus Plan. 
 (a) Employee shall be entitled to participation in the bonus compensation plan further defined in Section 3.2(b).
Additional detail of the bonus compensation plan will be provided in written detail to Employee once the bonus compensation plan is adopted by the Board, which will occur within a reasonable time after the Commencement Date. Any bonus or incentive
compensation paid to Employee shall be in addition to Base Compensation. 
 (b) Employee shall be eligible annually for a bonus to be
determined by the Board of up to 33.33% of Base Compensation. The amount of the bonus shall be determined by the Board, based on its reasonable assessment of Employee’s performance and the Company’s performance against appropriate goals
established annually by the Board or the Compensation Committee of the Board after consultation with the Executive, prior to the beginning of the period of time from which the performance of the Employee would be evaluated and measured for such
bonus. If all such goals are achieved for a given period, the amount of the bonus will be up to 33.33% of Base Compensation for that period. Employee’s bonus, as earned, shall be payable at the later of (i) the end of the first fiscal
quarter of the company following the end of the period for which the bonus was earned, or (ii) upon the issuance of the independent auditors’ report for the period ending when the bonus was earned. The first bonus period shall be for the
period commencing on the Commencement Date and ending at the last day of the Company’s fiscal year in which the Commencement Date occurs, unless the Board reasonably determines that results in a stub bonus period that is so short as to be
impractical (in which event the first bonus period shall be said stub bonus period plus the next full Company fiscal year after the Company fiscal year in which the Commencement Date occurs). Thereafter, the bonus plan period shall be the Company
fiscal year. 
 3.3 Stock Options and Restricted Stock Grant. 

(a) From time to time the Company may grant to Employee options under the Company’s Stock Option Plan (or its successor stock plan) to
purchase shares of the Company’s common stock at a stated exercise price per share. 
 (b) Effective on the Date of Approval by the
Compensation Committee, the Company shall grant to Employee a stock option under the 2011 Stock Option Plan (the “Plan”) to purchase 90,000 shares of Common Stock, with the exercise price of the stock options fixed under the Plan as of
such Approval Date, with the option to be treated as an incentive stock option to the greatest extent permitted by law and a non-qualified stock option as to the balance, vesting in accordance with the notice of stock option grant and stock option
grant attached hereto as Exhibit B (the “Stock Options”); provided however that Employee understands that there is no current availability of options or other securities under the Plan, so that the grant of such Stock Options is subject to
and conditioned upon shareholder approval of an amended and restated Plan at the Company’s 2014 annual meeting of stockholders. If the amended and restated Plan is not approved by the shareholders, the parties will negotiate in good faith to
provide alternative benefits for Employee. 
 (c) Effective on the Date of Approval by the Compensation Committee the Company shall grant to
Employee 10,000 shares restricted stock under the 2011 Stock Option Plan (the “Plan”). The 

  
 2 








 
restricted stock will vest over three (3) years in equal annual increments as outlined in Exhibit A (the “Restricted Stock”); provided however that Employee understands that there
is no current availability of restricted stock or other securities under the Plan, so that the grant of such Restricted stock is subject to and conditioned upon shareholder approval of an amended and restated Plan at the Company’s 2014 annual
meeting of stockholders. If the amended and restated Plan is not approved by the shareholders, the parties will negotiate in good faith to provide alternative benefits for Employee. 

(d) The Company covenants and agrees to use reasonable efforts take such further steps as may be necessary, if any, to increase the number of
shares of common stock reserved for issuance pursuant to the 2011 Stock Option Plan, so as to enable the Incentive Stock Options and the Non-Qualified Stock Options to be issued by the Company to the Employee. 

3.4 Benefits. Employee and his dependents shall be entitled to such medical/dental, disability and life insurance coverage and such
401(k) plan and other retirement plan participation, vacation, sick leave and holiday benefits, if any, and any other benefits as are made available either to Company’s other senior executives or to the Company’s personnel generally, all
in accordance with the Company’s benefits program in effect from time to time. The Employee is responsible for paying the employee’s portion of the benefit costs consistent with other relevant employees of the Company. The medical/dental,
disability and life benefits provided to Employee under this Section 3.4 shall continue until, and shall terminate, six (6) months after a Termination Event pursuant to Section 4 or Section 5 hereof, except to the extent that
Employee receives comparable benefits at a future employer during the six (6) months after the Termination Event, in which case the pertinent benefits from the Company shall end upon Employee’s enrollment in the future employer’s
benefit plan. 
  

	 	3.5	Reimbursement of Expenses. Employee shall be entitled to be reimbursed for all reasonable expenses including the cost of travel for business; home office operation; business meals and entertainment, incurred by
Employee in performing his tasks, duties and responsibilities under Sections 2.1 and 2.2 or otherwise in connection with and reasonably related to the furtherance of the Company’s business. Employee shall submit expense reports and receipts
documenting the expenses incurred in accordance with Company policy, and will comply with using the Company’s electronic T&E software and travel planning systems. 


 

	 	3.6	Mobile Device & Phones. The Company shall provide a mobile phone that is compliant with the Company policy and is HIPPA compliant. The Employee is welcome to use his own device or phone, but it must be
registered with the I.T. department and must follow the Company’s “BYOD” (Bring Your Own Device) policies, including but not limited to setting up of passwords, backups of information and compliance with email and communication
policies. 

 3.6 Moving Expenses. Intentionally Omitted.  

4. Change of Control. 
 4.1 In the event
of a termination of Employee’s employment hereunder by the Company with or without Cause or by Employee with or without Good Reason, within 12 months following a Change of Control, the Company will promptly pay Employee, in lieu of the amounts
required under Section 5.2(b) and in addition to the amounts required under Sections 3.4, 3.5 and 5.2(a), a severance amount, payable in a lump sum immediately upon the later of such termination of employment or Employee’s execution of a
Release in the form attached as Exhibit C (whether or not executed by the Company), equal to twelve (12) months base compensation, plus an amount equal to the prior year bonus. 

  
 3 








 4.2 As used herein, a “Change of Control” of the Company shall mean any of the
following: (i) the acquisition by any person(s) (individual, entity or affiliated or unaffiliated group) in one or a series of transactions (including, without limitation, issuance of shares by the Company or through merger of the Company with
another entity) of direct or indirect record or beneficial ownership of 50% or more of the voting power with respect to matters put to the vote of the shareholders of the Company and, for this purpose, the terms “person” and
“beneficial ownership” shall have the meanings provided in Section 13(d) or 14(d) of the Securities Exchange Act of 1934 or related rules promulgated by the Securities and Exchange Commission; (ii) the commencement of or public
announcement of an intention to make a tender or exchange offer for more than 50% of the then outstanding Shares of the common stock of the Company; (iii) a sale of all or substantially all of the assets of the Company; or (iv) the Board,
in its sole and absolute discretion, determines that there has been a sufficient change in the stock ownership of the Company to constitute a change in control of the Company. Notwithstanding the foregoing, the following acquisitions shall not
constitute a “Change of Control”: (1) any capital raised by the Company (not used for a redemption of outstanding shares); (2) the closing of any transaction that in good faith may be reasonably characterized as an acquisition of
another entity by the Company rather than the other way around; or (3) any acquisition of the Company or its shares by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the
Company. 
 5. Termination 
 5.1
Termination Events. The employment hereunder will terminate upon the occurrence of any of the following events (“the Termination Event”): 

(a) Employee dies; or 
 (b) The
Company, by written notice to Employee or his personal representative, discharges Employee due to the inability to continue to perform the duties previously assigned to Employee hereunder prior to such injury, illness or disability for a continuous
period exceeding 90 days or 180 out of 360 days by reason of injury, physical or mental illness or other disability, which condition has been certified by a physician reasonably acceptable to the Company; provided, however, that prior to discharging
Employee due to such disability, the Company shall give a written statement of findings to Employee or his personal representative setting forth specifically the nature of the disability and the resulting performance failures, and Employee shall
have a period of thirty (30) days thereafter to respond in writing to the Company’s findings, whereupon the Company shall conduct a reasonable and fair hearing with the Employee and any supporting witnesses and evidence for the Employee to
reach a final determination; or 
 (c) Employee is discharged by the Company for “Cause”. As used in this Agreement, the term
“Cause” shall mean: 
 (i) Employee’s final and unappealed conviction of (or pleading guilty or “nolo contendere”
to) any felony or a major misdemeanor involving dishonesty or moral turpitude; provided, however, that prior to discharging Employee for Cause, the Company shall give a written statement of findings to Employee setting forth specifically the grounds
on which Cause is based, and Employee shall have a period of ten (10) days thereafter to respond in writing to the Company’s findings; or 

(ii) The Employee’s (1) unreasonable failure to perform his duties, as determined by the Board of Directors, or
(2) substantial and material breach of, or default under, this Agreement or the Proprietary Information and Invention Assignment Agreement (as defined herein). (3) The unreasonable failure of the Company, as determined by the Board of
Directors, to meet reasonable benchmarks that are in control of the Employee, as may be agreed to from time to time by 

  
 4 








 
the Employee and the Board of Directors. In the case of any of the conditions set forth in this Section 5.1(c)(ii), the Employee shall be given written notice of the intent of the Board of
Directors to terminate the Employee’s employment under this paragraph, and shall be permitted thirty (30) days from receipt of such written notice to promptly cure any such breach or default to the reasonable satisfaction of the Board of
Directors. 
 (d) Employee is discharged by Company other than in accordance with Section 5.1(a)-(c) (a termination “without
Cause”), which the Company may do at any time, with at least thirty (30) advance written notice, subject to the full performance of the obligations of the Company to the Employee pursuant to Section 4 or Section 5.2, as the case
may be; or 
 (e) Employee voluntarily terminates his employment due to “Good Reason”, which shall mean (i) a material
default by the Company in the performance of any of its obligations hereunder, which default remains uncured by the Company for a period of thirty (30) days following receipt of written notice thereof to the Company from Employee; (ii) a
material diminution of the roles, responsibilities or duties and/or the position, title or authority of Employee hereunder; or (iii) a requirement that Employee report to any person(s) other than the CEO or the Chairman of the Board; or 

(f) Employee voluntarily terminates his employment without Good Reason, which Employee may do at any time with at least 30 days advance
notice. 
 5.2 Effects of Termination. 

(a) Upon termination of Employee’s employment hereunder for any reason, the Company will promptly pay Employee all Base Compensation owed
to Employee and all bonuses earned, as previously defined in writing by the Company, and unpaid through the date of termination (including, without limitation, salary and employee expenses reimbursements). Employee shall be paid for any performance
bonus plan then in effect on a pro rata basis for that period of time during the fiscal year in which termination occurs, but such amount, if any shall only be paid at a commensurate time as other employees are paid their bonus amounts. 

(b) Unless Section 4 applies (in which case Section 4, and not this Section 5.2(b), will be followed), and in addition to the
amounts required under Sections 3.4, 3.5 and 5.2(a): 
 (i) Upon termination of Employee’s employment under Sections 5.1(a), Company
shall continue to pay the Base Compensation to the estate of the Employee for a period of ninety (90) days after such death. 
 (ii)
Upon termination of Employee’s employment under Section 5.1(b), the Company shall pay Employee, commencing immediately upon such termination of employment, monthly (or biweekly at the Company’s discretion) amounts equal to the then
applicable Base Compensation, excluding bonus, for a period of twelve (12) months after termination. 
 (iii) Upon termination of
Employee’s employment under Section 5.1(d) or 5.1(e), the Company shall pay Employee, commencing immediately upon the later of such termination of employment or Employee’s execution of a Release in the form attached as Exhibit C
(whether or not executed by the Company), monthly (or biweekly at the Company’s discretion) amounts equal to the then applicable Base Compensation, excluding bonus, for a period of six (6) months after termination. 

  
 5 








 (c) Upon termination of Employee’s employment hereunder pursuant to Sections 5.1(b), 5.1(c),
5.1(d), 5.1(e) or 5.1(f), Employee agrees that for the twelve (12) month period following the Termination Event: 
 (i) Employee will
not directly, whether as an individual, employee, director, consultant or advisor, or in any other capacity whatsoever other than a passive investor, provide services to any person, firm, corporation or other business enterprise which is involved in
the business of development, marketing or providing a diagnostic service offering of proprietary DNA probes or microarrays or next generation sequencing to cancer researchers or physician practitioners or biotech and pharma companies that serve the
cancer markets and categories in direct competition with the Company (“Competitive Engagements”), unless Employee obtains the Company’s prior written consent. 

(ii) Employee will not knowingly, directly and actively solicit any individual to leave the Company’s then full-time employ, for any
reason, to join or be employed by any employer that then employs Employee as an employee, director, consultant or advisor. 
 (iii)
Employee will not knowingly, directly and actively induce any provider, agent, customer, supplier, distributor, or licensee of the Company to cease doing business with the Company or to breach its agreement with the Company. 

(d) Employee acknowledges that monetary damages may not be sufficient to compensate the Company for any economic loss, which may be incurred
by reason of breach of the restrictive covenants set forth in Section 5.2(c). Accordingly, in the event of any such breach, the Company shall, in addition to any remedies available to the Company at law, be entitled to seek equitable relief in
the form of an injunction, precluding Employee from continuing to engage in such breach. 
 (e) If any restriction set forth in
Section 5.2(c) is held to be unreasonable, then Employee and the Company agree, and hereby submit, to the reduction and limitation of such prohibition to such area or period as shall be deemed reasonable 

(f) Except as required by law, Employee agrees not to make to any person, including but not limited to customers of the Company, any statement
that disparages the Company or which reflects negatively upon the Company, including but not limited to statements regarding the Company’s financial condition, its officers, directors, shareholders, employees and affiliates. The Company agrees
not to make to any person, including but not limited to customers of the Company, any statement that disparages Employee or which reflects negatively upon Employee, including but not limited to statements regarding his financial condition. 

6. Conflicts of Interest 
 6.1 Duty to
Disclose. Employee will provide the CEO and Board with a report on the existence of any actual conflicts of interest. In connection with any actual conflicts of interests, Employee will confidentially disclose the existence of any conflicts of
interests, including his financial interest and the minimum about of facts necessary to assess the conflict of interest, to the CEO and Board or to any special committees with Board delegated powers considering the proposed transaction or
arrangement. If the Board or committee has reasonable cause to believe that Employee has failed to disclose any actual conflict of interest, it shall inform Employee of the basis for such belief and afford Employee an opportunity to explain the
alleged failure to disclose. 
 6.2 Determining Whether a Conflict of Interest Exists. After disclosure of the financial
interest and the minimum about of facts necessary to assess the conflict of Interest, and after any 

  
 6 








 
discussion with the Employee, Employee shall excuse himself from the Board or committee meeting while the determination of whether a conflict of interest exists is discussed and voted upon. The
remaining Board or committee members shall determine whether a conflict of interest exists. Notwithstanding the foregoing, however, prior approval of the Board of Directors shall not be required if the transaction falls below a de minimis
threshold established by the Board. 
 6.3 Addressing Conflict. If the Board determines that Employee has an actual conflict of
interest, the Company and Employee shall employ good faith actions to resolve the conflict of interest. 
 7 General Provisions 

7.1 Assignment. Neither party may assign or delegate any of his or its rights or obligations under this Agreement without the prior
written consent of the other party. 
 7.2 Entire Agreement. This Agreement contains the entire agreement between the parties with
respect to the subject matter hereof and supersedes any and all prior written and verbal agreements between the parties. 
 7.3
Modifications. This Agreement may be changed or modified only by an agreement in writing signed by both parties hereto. 
 7.4
Successors and Assigns. The provisions of this Agreement shall inure to the benefit of, and be binding upon, the Company and its successors and permitted assigns and Employee and Employee’s legal representatives, heirs, legatees,
distributees, assigns and transferees by operation of law, whether or not any such person shall have become a party to this Agreement and have agreed in writing to join and be bound by the terms and conditions hereof. 

7.5 Governing Law. This Agreement shall be governed by, construed and enforced in accordance with, the laws of the State of New Jersey,
and venue and jurisdiction for any disputes hereunder shall be heard in any court of competent jurisdiction in New Jersey for all purposes. 

7.6 Severability. If any provision of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable,
the remaining provisions shall nevertheless continue in full force and effect. 
 7.7 Further Assurances. The parties will execute
such further instruments and take such further actions as may be reasonably necessary to carry out the intent of this Agreement. 
 7.8
Notices. Any notices or other communications required or permitted hereunder shall be in writing and shall be deemed received by the recipient when delivered personally or, if mailed, five (5) days after the date of deposit in the United
States mail, certified or registered, postage prepaid and addressed, in the case of the Company, to its corporate headquarters, attention CEO, and in the case of Employee, to the address shown for Employee on the signature page hereof, or to such
other address as either party may later specify by at least ten (10) days advance written notice delivered to the other party in accordance herewith. 

7.9 No Waiver. The failure of either party to enforce any provision of this Agreement shall not be construed as a waiver of that
provision, nor prevent that party thereafter from enforcing that provision of any other provision of this Agreement. 

  
 7 








 7.10 Legal Fees and Expenses. In the event of any disputes under this Agreement, each
party shall be responsible for their own legal fees and expenses which it may incur in resolving such dispute, unless otherwise prohibited by applicable law or a court of competent jurisdiction. 

7.11 Counterparts. This Agreement may be executed by exchange of facsimile signature pages and/or in counterparts, each of which shall
be deemed to be an original, but all of which together shall constitute one and the same instrument. 
 7.12 Insurance on Employee.
The Company shall be entitled to obtain and maintain, at the Company’s expense, key person life insurance on the life of the Employee, naming the Company as the beneficiary of such policy. Employee agrees to cooperate with the Company and take
all reasonable actions necessary to obtain such insurance, such as taking usual and customary physical examinations and providing true and accurate personal, health related information for any application at no cost to Employee. 

7.13 Proprietary Information and Invention Assignment Agreement. The terms of the proprietary information and invention assignment
agreement attached hereto as Exhibit D (the “Proprietary Information and Invention Assignment Agreement”) are incorporated herein by reference. If there is any conflict between the terms of the Proprietary Information and Invention
Assignment Agreement and the terms of this Agreement, the terms of this Agreement shall prevail. 
 [Signature Page To Follow] 

  
 8 








 IN WITNESS WHEREOF, the Company and Employee have executed this Agreement, effective as of the
day and year first above written. 
  

					
		 	CANCER GENETICS, INC.:
		
	By:	 	 /s/ Panna Sharma

		 	Name:	 	Panna Sharma
		 	Title:	 	Chief Executive Officer
		
		 	EMPLOYEE:
		
		 	 /s/ Edward J. Sitar

		 	Edward J. Sitar

 Address: 
 39 Flaming Arrow Road

 Mahwah, New Jersey 07430 

  
 9 








 EXHIBIT A 

NOTICE OF GRANT OF 10,000 RESTRICTED STOCK 

VESTING SCHEDULE 
  

					
	 Date
	  	Amount Vested	 
		
	 March 17, 2015
	  	 	3,334 shares	  
		
	 March 17, 2016
	  	 	3,333 shares	  
		
	 March 17, 2017
	  	 	3,333 shares	  


  
 10 








 EXHIBIT B 

NOTICE OF GRANT OF 90,000 STOCK OPTIONS 

VESTING SCHEDULE 
  

					
	 Date
	  	Amount Vested*	 
	 Start - July 17, 2014
	  	 	4,500	  
	 10/17/2014
	  	 	9,000	  
	 1/17/2015
	  	 	13,500	  
	 4/17/2015
	  	 	18,000	  
	 7/17/2015
	  	 	22,500	  
	 10/17/2015
	  	 	27,000	  
	 1/17/2016
	  	 	31,500	  
	 4/17/2016
	  	 	36,000	  
	 7/17/2016
	  	 	40,500	  
	 10/17/2016
	  	 	45,000	  
	 1/17/2017
	  	 	49,500	  
	 4/17/2017
	  	 	54,000	  
	 7/17/2017
	  	 	58,500	  
	 10/17/2017
	  	 	63,000	  
	 1/18/2018
	  	 	67,500	  
	 4/18/2018
	  	 	72,000	  
	 7/18/2018
	  	 	76,500	  
	 10/18/2018
	  	 	81,000	  
	 1/18/2019
	  	 	85,500	  
	 Final - 4/18/2019
	  	 	90,000	  

  

	*	For purpose of clarity, the total accumulated amount of vested options are shown in the table above. 


  
 11 








 EXHIBIT C 

RELEASE 
 The undersigned
individual (“Releasor”), on his own behalf and on behalf of his heirs, beneficiaries and assigns, hereby releases and forever discharges Cancer Genetics, Inc. and its subsidiaries and all of their respective officers and directors,
successors and assigns (collectively, “Released”), both individually and in their official capacities, from any and all liability, claims, demands, actions and causes of action of any type (collectively, “Claims”) which Releasor
has had in the past, now has, or might now have, through the date of your execution of this Release, in any way resulting from, arising out of or connected with your employment by Cancer Genetics, Inc. and its subsidiaries (collectively,
“Company”) or its termination or pursuant to any federal, state or local employment law, regulation or other requirement (including without limitation Title VII of the Civil Rights Act of 1964, as amended; the Age Discrimination in
Employment Act, as amended (“ADEA”); the Americans with Disabilities Act, as amended). 
 The Company, on its own behalf and on
behalf of the Released, hereby releases and forever discharges the Releasor and his heirs, beneficiaries and representatives and assigns, both individually and in their official capacities, from any and all Claims which it has had in the past, now
has, or might now have, through the date of your execution of this Release, in any way resulting from, arising out of or connected with your employment by the Company or its termination. By acceptance of or reliance on this release of Claims by
Releasor, the Company promises that neither it nor any of the other Released affiliated with the Company will take any action that is designed, specifically as to you or with respect to a class of similarly situated former employees, to reduce or
abrogate, or may reasonably be expected to result in an abridgement or elimination of, any rights of indemnification or contribution available to Releasor, as described above, or under any such policy or policies of directors and officers liability
insurance, unless any such abridgement or elimination of rights also is generally applicable to all then-current officers and employees of the Company. 

Excluded from the scope of this Release is (i) any claim by Releasor for payment of wages (including salary, bonus, severance, and unused
vacation pay or PTO) or reimbursement of expenses or under the terms of any of the Company’s employee qualified and non-qualified benefit plans (including without limitation the Company’s employee pension plan, profit sharing plan, stock
option plan or stock ownership plan); (ii) any claim or right of Releasor under any policy or policies of directors and officers liability insurance maintained by the Company as in effect from time to time; and (iii) any right of or for
indemnification or contribution pursuant to contract and/or the Articles of Incorporation or By-Laws (or other charter documents) of the Company that Releasor has or hereafter may acquire if any claim is asserted or proceedings are brought against
Releasor including, without limitation, if by any governmental or regulatory agency, or by any customer, creditor, employee or shareholder of the Company, or by any self-regulatory organization, stock exchange or the like, arising out of or related
or allegedly related to the undersigned individual being or having been an officer or employee of the Company or to any of his actions, inactions or activities as an officer or employee of the Company. Also excluded from this release are any Claims
which cannot be waived by law. By signing this Release you are waiving, however, your right to any monetary recovery should any governmental agency or entity, such as the EEOC or the DOL, pursue any claims on your behalf. Releasor acknowledges that
he is knowingly and voluntarily waiving and releasing any rights he may have under the ADEA, as amended. 
 The undersigned individual
further acknowledges that he has been advised by this writing that: (a) his waiver and release in this Release does not apply to any rights or claims that may arise after the execution date of this Release; (b) that he has the right to
consult with an attorney prior to executing this Release; (c) he has up to the entirety of until twenty-one (21) days after the date he received this Release 

  
 12 








 
executed by the Company in which to consider this Release (although if the undersigned individual does execute this Release before the end of such twenty-one (21) days, he will also sign the
Consideration Period waiver below); (d) she has seven (7) days following his execution of this Release to revoke this Agreement by so notifying the Company; and (e) this Release shall not be effective until the date upon which the
this seven (7) day revocation period has expired unexercised (the “Effective Date”), which shall be the eighth day after this Release is executed by the undersigned individual. Upon the lapse of said seven (7) day period without
revocation, this Release will have effect retroactively to the date it was signed by the Company. 
 This Release does not constitute an
admission by the Company or by the undersigned individual of any wrongful action or violation of any federal, state, or local statute, or common law rights, including those relating to the provisions of any law or statute concerning employment
actions, or of any other possible or claimed violation of law or rights. This Release is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such
promises, warranties or representations. This Release may not be modified or amended except in a writing signed by both the undersigned individual and a duly authorized officer of the Company. This Release will bind the heirs, personal
representatives, successors and assigns of both the undersigned individual and the Company, and inure to the benefit of both the undersigned individual and the Company and their respective heirs, successors and assigns. If any provision of this
Release is determined to be invalid or unenforceable, in whole or in part, this determination will not affect any other provision of this Release and the provision in question will be modified by the court so as to be rendered enforceable. This
Agreement will be deemed to have been entered into and will be construed and enforced in accordance with the laws of the state of New Jersey as applied to contracts made and to be performed entirely within New Jersey. 

 

											
	Cancer Genetics, Inc.	 		 		 	Edward J. Sitar
						
	By: [name], [position]	 	  
	 		 		 		 	  

						
	Date:	 		 		 		 		 	Date:

 CONSIDERATION PERIOD WAIVER 

I, Edward J. Sitar understand that I have the right to take at least 21 days to consider whether to sign this Release, which I received on
            ,             . If I elect to sign this Release before 21 days have passed, I understand I am to sign and date below
this paragraph to confirm that I knowingly and voluntarily agree to waive the 21-day consideration period. 
  

	
	Edward J. Sitar
	
	  

	
	Date:


  
 13 








 EXHIBIT D 

PROPRIETARY INFORMATION AND 

INVENTION ASSIGNMENT AGREEMENT 

  
 14